How China’s HGRAC Affects Global Rare Disease Trials
How China’s HGRAC Affects Global Rare Disease Trials The Impact of HGRAC Rules on Rare Disease Clinical Trials in China Introduction Rare disease clinical trials often depend on global collaboration, with sponsors seeking diverse genetic data and patient cohorts across regions. In China, the Human Genetic Resources Administration of China (HGRAC) plays a pivotal regulatory…
Read More “How China’s HGRAC Affects Global Rare Disease Trials” »